BRPI0208075B8 - processo para a preparação de compostos de imidazol - Google Patents

processo para a preparação de compostos de imidazol

Info

Publication number
BRPI0208075B8
BRPI0208075B8 BRPI0208075A BRPI0208075B8 BR PI0208075 B8 BRPI0208075 B8 BR PI0208075B8 BR PI0208075 A BRPI0208075 A BR PI0208075A BR PI0208075 B8 BRPI0208075 B8 BR PI0208075B8
Authority
BR
Brazil
Prior art keywords
methyl
imidazole compounds
chlorophenyl
preparing imidazole
quinolinone
Prior art date
Application number
Other languages
English (en)
Inventor
Laurent Maria Broeckx Rudy
Marcel Herman Leurs Stefan
Ferdinand Maria Filliers Walter
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR0208075A publication Critical patent/BR0208075A/pt
Publication of BRPI0208075B1 publication Critical patent/BRPI0208075B1/pt
Publication of BRPI0208075B8 publication Critical patent/BRPI0208075B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)

Abstract

"processo para a preparação de compostos de imidazol". a presente invenção refere-se a um processo para a preparação de 4-(3-clorofenil)-6-[(4-clorofenil)hidróxi(1-metil-1h-imidazol-5-il)metil]-1-metil-2(1h)-quinolinona, que compreende reagir 6-(4-clorobenzoil)-4-(3-clorofenil)-1-metil-2(1h)-quinolinona com um composto de (c~ 6-8~)alquillítio, 1-metilimidazol e um halogeneto de tri(c~ 4-6~)alquilsilila, para obter melhores rendimentos do produto acima.
BRPI0208075-3 2001-03-12 2002-03-05 processo para a preparação de compostos de imidazol BRPI0208075B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01200928.8 2001-03-12
EP01200928 2001-03-12
PCT/EP2002/002459 WO2002072574A1 (en) 2001-03-12 2002-03-05 Process for the preparation of imidazole compounds

Publications (3)

Publication Number Publication Date
BR0208075A BR0208075A (pt) 2004-03-02
BRPI0208075B1 BRPI0208075B1 (pt) 2018-02-14
BRPI0208075B8 true BRPI0208075B8 (pt) 2021-05-25

Family

ID=8180004

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0208075-3 BRPI0208075B8 (pt) 2001-03-12 2002-03-05 processo para a preparação de compostos de imidazol

Country Status (32)

Country Link
US (1) US6844439B2 (pt)
EP (1) EP1373255B1 (pt)
JP (1) JP4257698B2 (pt)
KR (1) KR100849042B1 (pt)
CN (1) CN1246318C (pt)
AR (1) AR035944A1 (pt)
AT (1) ATE287882T1 (pt)
AU (1) AU2002253101B2 (pt)
BR (1) BRPI0208075B8 (pt)
CA (1) CA2438421C (pt)
CZ (1) CZ300622B6 (pt)
DE (1) DE60202755T2 (pt)
DK (1) DK1373255T3 (pt)
EA (1) EA006770B1 (pt)
EE (1) EE05247B1 (pt)
ES (1) ES2236505T3 (pt)
HK (1) HK1063315A1 (pt)
HR (1) HRP20030695B1 (pt)
HU (1) HU230282B1 (pt)
IL (2) IL157839A0 (pt)
MX (1) MXPA03008205A (pt)
MY (1) MY124838A (pt)
NO (1) NO324954B1 (pt)
NZ (1) NZ528620A (pt)
PL (1) PL208238B1 (pt)
PT (1) PT1373255E (pt)
SI (1) SI1373255T1 (pt)
SK (1) SK287807B6 (pt)
TW (1) TWI249532B (pt)
UA (1) UA74871C2 (pt)
WO (1) WO2002072574A1 (pt)
ZA (1) ZA200307117B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2291455T3 (es) 2001-03-12 2008-03-01 Avanir Pharmaceuticals Compuestos de bencimidazol para modular ige e inhibir la proliferacion celular.
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
JP2007538004A (ja) * 2004-03-18 2007-12-27 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US7524961B2 (en) 2004-05-03 2009-04-28 Janssen Pharmaceutica, N.V. Diastereoselective addition of lithiated N-methylimidazole on sulfinimines
JP4917022B2 (ja) * 2004-05-03 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ６−ブロモ−４−（３−クロロフェニル）−２−メトキシ−キノリンを用いるジアステレオ選択的合成方法
ATE397600T1 (de) 2004-05-03 2008-06-15 Janssen Pharmaceutica Nv Diastereoselektives syntheseverfahren zur herstellung vn imidazolverbindungen
EP1968591A4 (en) 2005-12-23 2010-02-17 Link Medicine Corp TREATMENT OF SYNUCLEINOPATHIES
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
KR101044430B1 (ko) * 2009-09-25 2011-06-27 듀오백코리아 주식회사 요추받이를 포함하는 의자의 등 지지 장치
KR101107900B1 (ko) * 2009-10-21 2012-01-25 성용기업 주식회사 의자용 허리지지장치
PT3277842T (pt) 2015-08-17 2019-09-05 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
EP3838275A1 (en) 2016-11-03 2021-06-23 Kura Oncology, Inc. Farnesyltransferase inhibitors for use in methods of treating cancer
US10954210B2 (en) 2016-12-08 2021-03-23 Hangzhou Solipharma Co., Ltd. Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof
AU2019270163A1 (en) * 2018-05-18 2020-12-03 Kura Oncology, Inc. Synthesis of tipifarnib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
SI1162201T1 (sl) * 1995-12-08 2006-08-31 Janssen Pharmaceutica Nv (Imidazol-5-il)metil-2-kinolinonski derivati kot inhibitorji farnezil protein transferaze
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CA2288140C (en) 1997-04-25 2007-04-03 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
JP3495706B2 (ja) * 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗癌薬として有用なアルキニル置換キノリン−２−オン誘導体
ES2237125T3 (es) 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.

Also Published As

Publication number Publication date
CN1496363A (zh) 2004-05-12
CZ300622B6 (cs) 2009-07-01
NO20034003L (no) 2003-10-22
WO2002072574A1 (en) 2002-09-19
EA200300998A1 (ru) 2004-02-26
MY124838A (en) 2006-07-31
US20040138256A1 (en) 2004-07-15
SK12462003A3 (sk) 2004-06-08
MXPA03008205A (es) 2004-01-29
KR20030079971A (ko) 2003-10-10
HK1063315A1 (en) 2004-12-24
ZA200307117B (en) 2004-09-13
CA2438421A1 (en) 2002-09-19
PT1373255E (pt) 2005-05-31
HRP20030695B1 (en) 2011-07-31
NO20034003D0 (no) 2003-09-10
HRP20030695A2 (en) 2005-02-28
SI1373255T1 (pt) 2005-08-31
SK287807B6 (sk) 2011-10-04
HUP0303443A3 (en) 2012-09-28
TWI249532B (en) 2006-02-21
NO324954B1 (no) 2008-01-14
CZ20032704A3 (en) 2004-03-17
AR035944A1 (es) 2004-07-28
HUP0303443A2 (hu) 2004-01-28
AU2002253101B2 (en) 2007-08-09
CA2438421C (en) 2010-05-18
IL157839A (en) 2008-07-08
PL363263A1 (en) 2004-11-15
IL157839A0 (en) 2004-03-28
EE200300442A (et) 2003-12-15
EP1373255A1 (en) 2004-01-02
JP2004523575A (ja) 2004-08-05
DE60202755D1 (de) 2005-03-03
EP1373255B1 (en) 2005-01-26
BR0208075A (pt) 2004-03-02
CN1246318C (zh) 2006-03-22
PL208238B1 (pl) 2011-04-29
DK1373255T3 (da) 2005-05-23
EE05247B1 (et) 2009-12-15
KR100849042B1 (ko) 2008-07-29
ES2236505T3 (es) 2005-07-16
ATE287882T1 (de) 2005-02-15
BRPI0208075B1 (pt) 2018-02-14
US6844439B2 (en) 2005-01-18
DE60202755T2 (de) 2006-03-30
JP4257698B2 (ja) 2009-04-22
NZ528620A (en) 2005-01-28
UA74871C2 (en) 2006-02-15
EA006770B1 (ru) 2006-04-28
HU230282B1 (hu) 2015-12-28

Similar Documents

Publication Publication Date Title
BRPI0208075B8 (pt) processo para a preparação de compostos de imidazol
MA30952B1 (fr) Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la proteine kinase akt
TW200605877A (en) Formulation for stimulating hair growth
NZ525008A (en) Pyrazole compounds useful as protein kinase inhibitors
AP2004003059A0 (en) Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
EP2261218A3 (en) Process for preparing phenyl-, pyridinyl- or pyrimidinyl-substituted imidazoles
BR0213843A (pt) Derivado de quinazolina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, e, uso de um derivado de quinazolina
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
TN2010000130A1 (fr) Derives de quinazolinedione, leur preparation et leurs applications therapeutiques
NO20072795L (no) Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
BR0316879A (pt) Compostos quìmicos
PT1713475E (pt) Derivados de 4,5-diidro-1h-pirazol 1,3,5-trissubstituído tendo atividade antagonística a cb1
IS2750B (is) Leiðarafesting
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
BR0210028A (pt) Agentes antibacterianos
WO2002062794A3 (en) Compounds
WO2007076228A8 (en) 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
WO2004046101A3 (en) Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
AU2002325570A1 (en) New process for the preparation of optically active 2-(6-(substituted alkyl)-1,3-dioxan-4-yl)acetic acid derivatives
AU1185801A (en) Novel compounds
DK1474422T3 (da) R-(-)-1-[2-(7-chlorbenzo[b]thiophen-3-ylmethoxy)-2-(2,4-dichlorphenyl)ethyl]-1H imidazol
TW200610530A (en) Anti-parasitic uses of borinic acid complexes
BR0016673A (pt) Composto, composição, processos para preparar um composto e composições, composição, método para controlar vegetação indesejável e uso de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/03/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 05/03/2022